摘要
目的 比较尿激酶(UK)与重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性心肌梗死的效果.方法 急性心肌梗死患者72例,借助SAS统计分析系统,按随机数字表法分为rt-PA组和UK组,每组36例.记录两组患者冠脉血管再通率、出血事件、不良心血管事件和病死率,并测定两组患者的肌钙蛋白T(cTnT).结果 rt-PA组患者溶栓开始后0.5h、1h、2h冠脉血管再通率均显著高于对照组,差异有统计学意义(x2 =7.32、6.12、5.81,均P<0.05).rt-PA组出血事件3例、病死2例,UK组出血事件5例、病死3例,差异无统计学意义(x2=1.22,均P>0.05).rt-PA组共出现不良心血管事件6例,对照组14例(x2=4.56,P<0.05).rt-PA组病死2例,UK组死亡3例,两组病死率差异无统计学意义(x2=0.40,P>0.05).两组患者cTnT在入院6h、12h时均较入院时有显著升高(t=6.67、6.30、4.11、4.22、4.40,均P<0.05),两组比较,rtPA组在入院6h、12 h时cTnT显著低于UK组(t=5.92、6.61,均P<0.05).结论 相比UK,rt-PA治疗急性心肌梗死再通率高,不良事件少,心肌损伤小,值得临床推广应用.
Objective To compare the clinical effect of UK and rt-PA intravenous thrombolytic therapy for acute myocardial infarction. Methods By SAS statistical analysis system,72 patients with acute myocardial infarctionwere randomly divided into rt-PA group and UK group, each group had 36 cases. The coronary artery recanalization rate, bleeding events, adverse cardiovascular events, mortality, and cardiac, troponin T (eTnT) level were recorded. Results In rt-PA group,0.5h, 1 h,2h after the start of thrombolytic therapy, the coronary artery recanalization rate was significantly higher than that in the control group, the difference was statistically significant (X2 = 7.32,6.12, 5. 81 ,all P 〈0.05). In rt-PA group,3 cases had bleeding events ,2 cases died,and in UK group,5 cases had bleeding events ,3 eases died,, there was no statistically significant difference between the two groups ( X2 = 1.22, P 〉 0.05 ). In rt-PA group, there were 6 cases with adverse cardiovascular events, 14 cases in the control group, the difference was statistically significant (X2 = 4.56 ,P 〈 O. 05 ). 2 cases died in rt-PA group, 3 cases died in UK group, the mortality between the two groups had no statistically significant difference (P 〉 0.05 ). The cTnT level in the hospital 6h, 12h was significantly higher than admission in two groups ( t = 6.67,6.30,4.11,4.22,4.40, all P 〈 0.05 ). In rt-PA group,eTnT level in the hospital 6h, 12h was significantly lower than that in UK group (t = 5.92,6.61, all P 〈 0.05 ). Conclusion Compared with UK, rt-PA in the treatment of acute myocardial infarction can increase recanali- zation rate, decrease adverse events and myocardial injury,it is worthy of clinical application.
出处
《中国基层医药》
CAS
2013年第20期3111-3113,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
心肌梗死
尿纤溶酶原激活物
重组酶类
血栓溶解疗法
Myocardial infarction
Urinary plasminogen activator
Recombinases
Thrombolytic therapy